Across TCGA pan-cancer cohorts, HSF1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSF1 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HSF1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSF1 expression acts as an unfavorable survival marker.

LIHC, BLCA, and PRAD are the cancer types where HSF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.093	0.530	.002	15	view →
BLCA	DFS	Median	All	0.121	0.594	.009	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HSF1 tumor-vs-normal RNA expression · all HSF1 data types